erlotinib hydrochloride has been researched along with evodiamine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (evodiamine) | Trials (evodiamine) | Recent Studies (post-2010) (evodiamine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 336 | 1 | 240 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | evodiamine (IC50) |
|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | 0.44 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 2.1 | |
| Cholinesterase | Equus caballus (horse) | 4.62 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, JY; Li, YL; Lin, NM; Mao, SY; Pan, JP; Pan, YN; Sun, J; Wu, WJ; Zhang, C; Zhang, DY; Zhao, YM | 1 |
1 other study(ies) available for erlotinib hydrochloride and evodiamine
| Article | Year |
|---|---|
Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2016 |